Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window ...

Overall, the study’s findings support the use of Amjevita and Imraldi as equally effective alternatives to Humira in the real ...

AbbVie’s Humira was the top-selling drug in the world for many years. Now, its sales are eroding as doctors switch to ...

Symptoms can include itching, pain, or swelling. Humira can also cause new or worsen psoriasis, a condition Humira is approved to treat. Psoriasis is a skin condition that causes symptoms such as ...

Until about 20 years ago, systemic treatment options for moderate/severe psoriasis were limited and ... "I still put a lot of ...

Humira is already off-patent and losing ground to rivals in Europe, although AbbVie’s legal defences have so far held fast in the US, preventing competition from biosimilars until 2023.

with the latter two rivalling Humira in indications such as rheumatoid arthritis and psoriasis. Kavya Gopal, head of specialty at Sandoz UK, said: “Biosimilars offer the NHS the potential to ...